20172 - PH 2 Enfortumab in Urothelial Pts

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Disease Types: Bladder,&nbs

Available at: {clinical_trial_location backspace="7"}20172 - PH 2 Enfortumab in Urothelial Pts, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}